Prosecution Insights
Last updated: November 18, 2026
Application No. 17/771,717

COMPOUNDS AND METHODS FOR PROMOTING PLANT GROWTH

Non-Final OA §102§103
Filed
Apr 25, 2022
Priority
Oct 24, 2019 — provisional 62/925,555 +1 more
Examiner
LOVE, TREVOR M
Art Unit
1611
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
UNIVERSITY OF TOKYO
OA Round
6 (Non-Final)
44%
Grant Probability
Moderate
6-7
OA Rounds
70%
With Interview

Examiner Intelligence

Grants 44% of resolved cases
44%
Career Allowance Rate
317 granted / 729 resolved
-16.5% vs TC avg
Strong +27% interview lift
Without
With
+26.6%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
49 currently pending
Career history
763
Total Applications
across all art units

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Acknowledgement is made to Applicant’s response filed 02/24/2026. Claims 1-7, 12, 16-18, 20, 21, 23, 27, 29, 30, 33, 34, 36, and 42 are pending. Claim 42 is newly added. Claim 1 is currently amended. Claims 20, 21, 23, 27, 29, 30, 33, 34, and 36 remain withdrawn. Claims 1-7, 12, 16-18, and 42 are currently under consideration to the extent that they read upon Applicant’s elected species: PNG media_image1.png 113 321 media_image1.png Greyscale Withdrawn Rejections The rejection of claim 7 under 35 U.S.C. 102(a)(1) as being anticipated by Welter et al (US 4370277) is withdrawn in view of Applicant’s cancellation of said claim. The rejection of claim 7 under 35 U.S.C. 103 as being unpatentable over Welter et al (US 4370277) is withdrawn in view of Applicant’s cancellation of said claim. Rejections Maintained and Made Again in view of Applicant’s Amendments with New Grounds for Newly Added Claim 42 Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1-6, 12, 16-18, and 42 (all claims currently under consideration) is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Welter et al (US 4370277). Welter teaches a compound of formula (II): PNG media_image2.png 158 318 media_image2.png Greyscale Wherein R1 is taught as being a C1 alkoxy (or OCH3), R2 is hydrogen, R3 is hydrogen, R4 is hydrogen, and R5 is a C1 alkyl (or CH3) (see entire document, for instance, column 1, lines 16-39). It is noted that this structure would be drawn as: PNG media_image1.png 113 321 media_image1.png Greyscale . The compound of formula II is taught as being combined with hydrocarbons, water, or an alcohol as a solvent (see entire document, for instance, column 2, lines 1-15). It is noted that MPEP 2131.02 states: “when the species is clearly named, the species claim is anticipated no matter how many other species are additionally named. Ex parte A, 17 USPQ2d 1716 (Bd. Pat. App. & Inter. 1990) (The claimed compound was named in a reference which also disclosed 45 other compounds. The Board held that the comprehensiveness of the listing did not negate the fact that the compound claimed was specifically taught)”. It is further noted that MPEP 2131.02 additionally states that “[i]f one of ordinary skill in the art is able to “at once envisage” the specific compound within the generic chemical formula, the compound is anticipated. One of ordinary skill in the art must be able to draw the structural formula or write the name of each of the compounds included in the generic formula before any of the compounds can be “at once envisaged.” One may look to the preferred embodiments to determine which compounds can be anticipated. In re Petering, 301 F.2d 676, 133 USPQ 275 (CCPA 1962)”, wherein further “[t]he limited number of compounds covered by the preferred formula in combination with the fact that the number of substituents was low at each site […] resulted in a finding that the reference sufficiently described “each of the various permutations here involved as fully as if he had drawn each structural formula or had written each name.” The claimed compound was 1 of these 20 compounds. Therefore, the reference “described” the claimed compound and the reference anticipated the claims”. It is further noted that “In re Schauman, 572 F.2d 312, 197 USPQ 5 (CCPA 1978), claims to a specific compound were anticipated because the prior art taught a generic formula embracing a limited number of compounds closely related to each other in structure and the properties possessed by the compound class of the prior art was that disclosed for the claimed compound. The broad generic formula seemed to describe an infinite number of compounds but claim 1 was limited to a structure with only one variable substituent R. This substituent was limited to low alkyl radicals. One of ordinary skill in the art would at once envisage the subject matter within claim 1 of the reference”. With regard to the limitation directed to the composition being present in “a range from about 1 µM to 100 µM” or “a range from about 1 µM to 10 µM”, and that the purpose of the compound of formula I being “to promote plant growth and/or inhibit growth of parasitic weed” it is noted that Welter teaches that the products of the process can be worked up in known manner, for example by dilution with water, acidification, extraction with an organic solvent, and separation of the solvent after drying by distillation. Welter also teaches that the novel compounds are obtained in the form of oils which can either be distilled or freed from the last volatile components by prolonged heating at moderately elevated temperature under reduced pressure, and thus purified (see entire document, for instance, column 2, lines 35-44). Further, it is noted that the methods of Welter are the making of the structures using the instantly claimed compound as a starting material. As such, on the front end of the process the compound would have a higher µM amount, and as the final product is being formed that µM would go down. As such, during the production of the product, the amount of the compound would fall within the instantly claimed range of about 1 µM to 100 µM or 1 µM to 10 µM. Further, in variant (a) the process includes additional components being present, such as water, thereby diluting the amount of the composition, which optimizes the µM amount. Response to Arguments and Declaration Applicant’s arguments and Declaration filed 09/09/2026 have been fully considered and are not found persuasive. Applicant argues in the Remarks filed 09/09/2026 that the prior art does not teach the instantly claimed micromolar amount. It is noted that the prior art teaches the instantly claimed structure as a main reagent in a process for making a different product. Applicant asserts on page 16 of the Remarks that the examples in the prior art teach a higher µM amount than is instantly claimed. It is noted that the prior art teaches the component as a reagent, wherein when the composition is diluted and the reagent used up, the micromolar amount goes down, ideally to zero. Along the way from a higher micromolar amount to zero, the instantly claimed composition is present. It is noted that the instant claims are directed to a product, not a method, wherein the product itself would be present in the prior art. It is noted that the instant declaration is not found persuasive. First, the declaration is not commensurate in scope with the breadth of the structures in claim 1. Second, even if the declaration had been commensurate (which it is not), unexpected results are not a persuasive argument with regard to rejections under 102. It is noted that the instantly claims are directed to a product not a method, wherein the prior art product is deemed to be capable of performing the intended uses articulated in the instant claims. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-6, 12, 16-18, and 42 (all claims currently under consideration) is/are rejected under 35 U.S.C. 103 as being unpatentable over Welter et al (US 4370277). Welter teaches a compound of formula (II): PNG media_image2.png 158 318 media_image2.png Greyscale Wherein R1 is taught as being a C1 alkoxy (or OCH3), R2 is hydrogen, R3 is hydrogen, R4 is hydrogen, and R5 is a C1 alkyl (or CH3) (see entire document, for instance, column 1, lines 16-39). It is noted that this structure would be drawn as: PNG media_image1.png 113 321 media_image1.png Greyscale . The compound of formula II is taught as being combined with hydrocarbons, water, or an alcohol as a solvent (see entire document, for instance, column 2, lines 1-15). Welter, while teaching a structure that directly overlaps the instantly claimed structure, does not draw out the structure in a singular image. It would have been obvious to one of ordinary skill in the art, before the effective filing date of the instantly claimed invention to utilize a structure of formula II, wherein R1 is OCH3, R2 is hydrogen, R3 is hydrogen, R4 is hydrogen, and R5 is CH3. One would have been motivated to do so since Welter expressly teaches that said components are useful for the formulation of formula II. With regard to the limitation directed to the composition being present in “a range from about 1 µM to 100 µM” or “a range from about 1 µM to 10 µM”, and that the purpose of the compound of formula I being “to promote plant growth and/or inhibit growth of parasitic weed” it is noted that Welter teaches that the products of the process can be worked up in known manner, for example by dilution with water, acidification, extraction with an organic solvent, and separation of the solvent after drying by distillation. Welter also teaches that the novel compounds are obtained in the form of oils which can either be distilled or freed from the last volatile components by prolonged heating at moderately elevated temperature under reduced pressure, and thus purified (see entire document, for instance, column 2, lines 35-44). Further, it is noted that the methods of Welter are the making of the structures using the instantly claimed compound as a starting material. As such, on the front end of the process the compound would have a higher µM amount, and as the final product is being formed that µM would go down. As such, during the production of the product, the amount of the compound would fall within the instantly claimed range of about 1 µM to 100 µM or about 1 µM to 10 µM. Further, in variant (a) the process includes additional components being present, such as water, thereby diluting the amount of the composition, which optimizes the µM amount. Response to Arguments and Declaration Applicant’s arguments and Declaration filed 09/09/2026 have been fully considered and are not found persuasive. Applicant argues in the Remarks filed 09/09/2026 that the prior art does not teach the instantly claimed micromolar amount. It is noted that the prior art teaches the instantly claimed structure as a main reagent in a process for making a different product. Applicant asserts on page 16 of the Remarks that the examples in the prior art teach a higher µM amount than is instantly claimed. It is noted that the prior art teaches the component as a reagent, wherein when the composition is diluted and the reagent used up, the micromolar amount goes down, ideally to zero. Along the way from a higher micromolar amount to zero, the instantly claimed composition is present. It is noted that the instant claims are directed to a product, not a method, wherein the product itself would be present in the prior art. It is noted that the instant declaration is not found persuasive for at least the reason that the declaration is not commensurate in scope with the breadth of the structures in claim 1. It is noted that the instantly claims are directed to a product not a method, wherein the prior art product is deemed to be capable of performing the intended uses articulated in the instant claims. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to TREVOR M LOVE whose telephone number is (571)270-5259. The examiner can normally be reached M-F typically 6:30-3. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bethany Barham can be reached at 5712726175. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /TREVOR LOVE/Primary Examiner, Art Unit 1611
Read full office action

Prosecution Timeline

Show 9 earlier events
Feb 24, 2026
Response Filed
Apr 09, 2026
Final Rejection mailed — §102, §103
Sep 09, 2026
Request for Continued Examination
Sep 09, 2026
Response after Non-Final Action
Sep 10, 2026
Response after Non-Final Action
Sep 24, 2026
Non-Final Rejection mailed — §102, §103
Sep 29, 2026
Applicant Interview (Telephonic)
Oct 01, 2026
Non-Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12797357
NANOPARTICLE ISOFLAVONE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
4y 9m to grant Granted Nov 17, 2026
Patent 12778124
A SYNERGISTIC PLANT GROWTH STIMULANT COMPOSITION COMPRISING MELATONIN AND NITROGENOUS COMPOUNDS FOR IMPROVING PLANT GROWTH AND DECREASING BIOTIC-ABIOTIC STRESSES ON PLANTS
3y 1m to grant Granted Nov 03, 2026
Patent 12778130
WATER CONDITIONERS FOR AGRICULTURAL FORMULATIONS
2y 11m to grant Granted Nov 03, 2026
Patent 12772975
INSECT REPELLENT-POLYMER GELS
2y 3m to grant Granted Oct 27, 2026
Patent 12740582
EXTRACTS FOR HEALTH SUPPLEMENTS
3y 6m to grant Granted Sep 22, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

6-7
Expected OA Rounds
44%
Grant Probability
70%
With Interview (+26.6%)
High
PTA Risk
Based on 729 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month